End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
30,050 KRW | +0.50% | -0.33% | -9.62% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Its low valuation, with P/E ratio at 7.1 and 6.24 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- With regards to fundamentals, the enterprise value to sales ratio is at 1077.82 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.62% | 325M | - | ||
+11.86% | 225B | B | ||
+12.03% | 186B | B- | ||
+13.91% | 135B | B- | ||
+27.04% | 107B | A- | ||
+0.91% | 63.56B | A- | ||
+6.74% | 51.32B | B+ | ||
+13.41% | 51.04B | B+ | ||
+8.89% | 43.3B | A | ||
+3.94% | 36.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A043150 Stock
- Ratings Value Added Technology Co., Ltd.